CDC Advisory Committee Recommends Booster Shot of Moderna's (MRNA) COVID-19 Vaccine

Moderna (MRNA) Enters MOU to Supply up to 110M COVID-19 Vaccine Doses to the African Union

October 26, 2021 5:50 AM EDT

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new Memorandum of Understanding (MoU) to make up to 110 million doses... More

Moderna (MRNA) Stock Plunges as Deutsche Bank Starts at Sell on Valuation, Sees 25% Downside

October 22, 2021 10:16 AM EDT

Deutsche Bank analyst Emmanuel Papadakis initiated the research coverage of Moderna (NASDAQ: MRNA) at Sell with a price target of $250.00 per share, signaling a potential downside of around 25%.

Despite the Sell rating, Papadakis praises MRNAs execution and the strategic discipline that has yielded massive returns in the past 12-18 months. However, the valuation at the moment is very high (+185% YTD).

We concur there is potential to disrupt dynamics in the broader viral infectious... More

Deutsche Bank Starts Moderna (MRNA) at Sell

October 22, 2021 4:04 AM EDT

(Updated - October 22, 2021 6:06 AM EDT)

Deutsche Bank analyst Emmanuel Papadakis initiates coverage on Moderna (NASDAQ: MRNA) with a Sell rating and a price target of $250.00.

The analyst comments "Moderna is a concept company that has ridden a wave of disruptive innovation, pandemic serendipity and management vision (plus a little public funding) to become a concept stock. Whilst execution has not been lacking, the strategic discipline to stay focused on mRNA is a virtue... More

CDC Advisers Back Moderna (MRNA) Booster for Older, at Risk Groups - Bloomberg

October 21, 2021 5:14 PM EDT

CDC Advisers Back Moderna (NASDAQ: MRNA) Booster for Older, at Risk Groups - Bloomberg

... More

Moderna (MRNA) Shares Tick Lower as White House Seeks WTO Support for Vaccine IP Waiver

October 21, 2021 2:50 PM EDT

Moderna (NASDAQ: MRNA) Shares Tick Lower as White House Seeks WTO Support for Vaccine IP Waiver

... More

Moderna (MRNA) Mix & Match Approval Means Booster Can Follow Any Other Vaccine - Piper Sandler

October 21, 2021 9:20 AM EDT

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $445.00 price target on Moderna (NASDAQ: MRNA) after the FDA granted Emergency Use Authorization (EUA) for SpikeVax booster 6 months following primary vaccination in adults a.) 65 and older, b.) 18-64yo at high-risk of... More

Moderna (MRNA) IV into COVID-19 vaccine boosters get FDA authorization

October 21, 2021 4:31 AM EDT

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 60; compared to its 52-week range of 51 to 131 into MRNA & Johnson & Johnson (JNJ) COVID-19 vaccine boosters get FDA authorization.

... More

FDA Takes Action to Expand the Use of a Booster Dose for Moderna and Janssen COVID-19 Vaccines

October 20, 2021 5:54 PM EDT

The U.S. Food and Drug Administration (FDA) amends the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose in eligible populations.

The use of a single booster dose of the Moderna (NASDAQ: MRNA)... More

Moderna (MRNA) Confirms FDA Authorization of Booster Dose of its COVID-19 Vaccine in the U.S.

October 20, 2021 5:38 PM EDT

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for... More

U.S. FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boost

October 20, 2021 5:02 PM EDT

By Ankur Banerjee and Michael Erman

(Reuters) -The U.S. Food and Drug Administration on Wednesday authorized booster doses of the COVID-19 vaccines from Moderna Inc and Johnson & Johnson, and said Americans can choose a different shot from their original inoculation as a booster.

That means all three vaccines authorized in the United States can also be given as boosters to some groups.

"The availability of these authorized boosters is important for continued protection against COVID-19 disease," acting FDA Commissioner Janet Woodcock said in a statement. She noted that data suggests vaccine effectiveness may wane... More

Moderna (MRNA), J&J (JNJ) Vaccine Booster EUAs Approved by FDA, Along with "Mix and Match" Booster Doses

October 20, 2021 4:50 PM EDT

Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations. The agency is amending the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose as follows:

The use of a single booster dose of the Moderna (NASDAQ: MRNA) COVID-19 Vaccine that may be administered at least 6 months after completion of the primary series to individuals:

65 years of age and older18 through 64 years of age at high risk of... More